Document is current
Any future updates will be listed below
-
Authors
Duranti, Claudia
Iorio, Jessica
Manganelli, Valeria
Bagni, Giacomo
Colasurdo, Rossella
Lottini, Tiziano
Martinelli, Michele
Capitani, Chiara
Boso, Giulia
D’Alessandro, Franco Nicolas
Sorice, Maurizio
Becchetti, Andrea https://orcid.org/0000-0002-9297-0527
Misasi, Roberta
Garofalo, Tina
Arcangeli, Annarosa https://orcid.org/0000-0002-6317-9648
-
Funding
Funding for this research was provided by:
Università degli Studi di Firenze (ex 60%)
Associazione Italiana per la Ricerca sul Cancro (1662, 15627, 21510)
- License Information
-
More Information
Article History
Received: 20 October 2024
Revised: 18 December 2024
Accepted: 22 January 2025
First Online: 3 February 2025
Competing interests
: CD, JI, and AA are named inventors on a patent covering the scDb-hERG1-β1 antibody in combination with cholesterol lowering drugs which has been issued by the University of Florence. All other authors declare no potential conflicts of interests.
: All methods were performed in accordance with the relevant guidelines and regulations. Patients were treated at Campus Bio-Medico University (Rome, Italy). Tissues were collected after informed written consent was obtained from all participants and approval of the local ethics committee (Reference number, PAR: 13.21) was granted. Animal experiments received the approval from the Italian Ministry of Health with the authorization number n. 963/2023-PR.
